Detalhe da pesquisa
1.
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
Ann Oncol
; 30(4): 589-596, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30689736
2.
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Ann Oncol
; 29(8): 1853-1860, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29982279